(Q24563021)

English

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study

scientific article

In more languages

default for all languages

No label defined

No description defined

Statements

scholarly article

0 references

Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomised, open-label, phase III study (English)

0 references

1

object named as

Pierre Fenaux

author given names

Pierre

author last names

Fenaux

1 reference

PubMed publication ID

1 November 2023

Eva Hellström-Lindberg

3

object named as

Eva Hellstrom-Lindberg

author given names

Eva

author last names

Hellstrom-Lindberg

1 reference

PubMed publication ID

1 November 2023

Valeria Santini

object named as

Valeria Santini

4

author given names

Valeria

author last names

Santini

1 reference

PubMed publication ID

1 November 2023

Guillermo F Sanz

object named as

Guillermo Sanz

9

author given names

Guillermo

author last names

Sanz

1 reference

PubMed publication ID

1 November 2023

object named as

Alan List

10

author given names

Alan

author last names

List

1 reference

PubMed publication ID

1 November 2023

14

object named as

John Byrd

author given names

John

author last names

Byrd

1 reference

PubMed publication ID

1 November 2023

Aristoteles A N Giagounidis

6

object named as

Aristoteles Giagounidis

author given names

Aristoteles

author last names

Giagounidis

1 reference

PubMed publication ID

1 November 2023

Norbert Gattermann

8

object named as

Norbert Gattermann

author given names

Norbert

author last names

Gattermann

1 reference

PubMed publication ID

1 November 2023

15

object named as

Jay Backstrom

author given names

Jay

author last names

Backstrom

1 reference

PubMed publication ID

1 November 2023

Lewis B Silverman

19

object named as

Lewis R Silverman

author given names

Lewis R

author last names

Silverman

1 reference

PubMed publication ID

1 November 2023

author name string

Ghulam J Mufti

2

author given names

Ghulam J

author last names

Mufti

1 reference

PubMed publication ID

1 November 2023

Carlo Finelli

5

author given names

Carlo

author last names

Finelli

1 reference

PubMed publication ID

1 November 2023

Robert Schoch

7

author given names

Robert

author last names

Schoch

1 reference

PubMed publication ID

1 November 2023

Steven D Gore

11

author given names

Steven D

author last names

Gore

1 reference

PubMed publication ID

1 November 2023

John F Seymour

12

author given names

John F

author last names

Seymour

1 reference

PubMed publication ID

1 November 2023

John M Bennett

13

author given names

John M

author last names

Bennett

1 reference

PubMed publication ID

1 November 2023

Linda Zimmerman

16

author given names

Linda

author last names

Zimmerman

1 reference

PubMed publication ID

1 November 2023

David McKenzie

17

author given names

David

author last names

McKenzie

1 reference

PubMed publication ID

1 November 2023

Cl Beach

18

author given names

Cl

author last names

Beach

1 reference

PubMed publication ID

1 November 2023

language of work or name

0 references

publication date

March 2009

0 references

Lancet Oncology Commission

0 references

10

0 references

3

0 references

223-32

0 references

International scoring system for evaluating prognosis in myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

24 March 2017

Proposals for the classification of the myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

24 March 2017

Modes of action of the DNA methyltransferase inhibitors azacytidine and decitabine.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

Allogeneic stem cell transplantation for myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

Definitions and standards in the diagnosis and treatment of the myelodysplastic syndromes: Consensus statements and report from a working conference

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

Myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

A phase II study of intensive chemotherapy with fludarabine, cytarabine, and mitoxantrone in P glycoprotein-negative high-risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

Revised recommendations of the International Working Group for Diagnosis, Standardization of Response Criteria, Treatment Outcomes, and Reporting Standards for Therapeutic Trials in Acute Myeloid Leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

Randomized controlled trial of azacitidine in patients with the myelodysplastic syndrome: a study of the cancer and leukemia group B.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

Report of an international working group to standardize response criteria for myelodysplastic syndromes.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

Evaluation of survival data and two new rank order statistics arising in its consideration

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

Low-dose ara-C in acute nonlymphocytic leukemia and myelodysplastic syndromes: a review of 20 years' experience

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

The evaluation of low-dose cytarabine in the treatment of myelodysplastic syndromes: a phase-III intergroup study

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

27 September 2017

Myelodysplastic syndromes: introduction

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

30 May 2018

World Health Organization classification of neoplastic diseases of the hematopoietic and lymphoid tissues: report of the Clinical Advisory Committee meeting-Airlie House, Virginia, November 1997.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

30 May 2018

S-HAM induction chemotherapy with or without GM-CSF in patients with high-risk myelodysplastic syndromes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

30 May 2018

Efficacy of intensive chemotherapy for acute myelogenous leukemia associated with a preleukemic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

30 May 2018

Hypomethylation and apoptosis in 5-azacytidine-treated myeloid cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

28 November 2018

Long-term follow-up results of the combination of topotecan and cytarabine and other intensive chemotherapy regimens in myelodysplastic syndrome

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

28 November 2018

Intensive chemotherapy with idarubicin, cytarabine, etoposide, and G-CSF priming in patients with advanced myelodysplastic syndrome and high-risk acute myeloid leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

28 November 2018

Evidence- and consensus-based practice guidelines for the therapy of primary myelodysplastic syndromes. A statement from the Italian Society of Hematology.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

28 November 2018

Comparison of idarubicin + ara-C-, fludarabine + ara-C-, and topotecan + ara-C-based regimens in treatment of newly diagnosed acute myeloid leukemia, refractory anemia with excess blasts in transformation, or refractory anemia with excess blasts

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

28 November 2018

Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4086808

28 November 2018

Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19230772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A predictive model for the clinical response to low dose ara-C: a study of 102 patients with myelodysplastic syndromes or acute leukaemia

1 reference

https://pubmed.ncbi.nlm.nih.gov/19230772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Is there still a role for low-dose cytosine arabinoside in de novo acute myeloid leukemia in the elderly? A report on 77 cases

1 reference

https://pubmed.ncbi.nlm.nih.gov/19230772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Standard and low-dose chemotherapy for the treatment of myelodysplastic syndromes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19230772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

CDKN2B methylation status and isolated chromosome 7 abnormalities predict responses to treatment with 5-azacytidine

1 reference

https://pubmed.ncbi.nlm.nih.gov/19230772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Intensive chemotherapy is not recommended for patients aged >60 years who have myelodysplastic syndromes or acute myeloid leukemia with high-risk karyotypes

1 reference

https://pubmed.ncbi.nlm.nih.gov/19230772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment

1 reference

https://pubmed.ncbi.nlm.nih.gov/19230772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms

1 reference

https://pubmed.ncbi.nlm.nih.gov/19230772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Results of intensive chemotherapy in 998 patients age 65 years or older with acute myeloid leukemia or high-risk myelodysplastic syndrome: predictive prognostic models for outcome

1 reference

https://pubmed.ncbi.nlm.nih.gov/19230772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Allogeneic stem cell transplantation for patients with acute myeloid leukemia or myelodysplastic syndrome who have chromosome 5 and/or 7 abnormalities

1 reference

https://pubmed.ncbi.nlm.nih.gov/19230772

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Nonparametric Estimation from Incomplete Observations

1 reference

https://api.crossref.org/works/10.1016%2FS1470-2045%2809%2970003-8

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

10.1016/S1470-2045(09)70003-8

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

release_zgcudj3hwjaw3kiuwkoj7zhptq

0 references

OpenCitations bibliographic resource ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PMC publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

PubMed publication ID

1 reference

Consolidated OpenCitations Corpus – April 2017

OpenCitations bibliographic resource ID

ResearchGate publication ID

0 references

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q24563021&oldid=2002427207"